Oncology Healthcare companies

Igniting the path to sustainable and affordable innovation.

We invest in cancer innovation, together.

Since our founding in 1976, Sofinnova has been active in life science investing and has primarily focused on therapeutic drugs over the last decade.

Investing in innovation for impact. Reduce cancer mortality and advance health equity.

Debiopharm invests in Smart Data & Digital Health companies developing technologies that are applicable in the areas of oncology or infectious diseases.

Accelerating life-extending therapies, treatments and cures for all myeloma patients.

At Third Rock, we push the boundaries of science and technology to make a difference in the lives of patients and their families.

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives.

Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.

Since 2004, Amgen Ventures has invested in emerging companies to help discover promising medicines and technologies that will bring "Value Healthcare" to patien…

Investing in the future of medicine.

We fund startups solving stigmatized healthcare problems.

Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world.

Pappas Capital invests exclusively in the life science sector.

Mass General Brigham Ventures is an early-stage venture capital firm founded in 2008 to advance new life science technologies emerging from Mass General Brigham…

Finchley Healthcare Ventures (FHCV) is a Canadian venture capital fund founded in 2022 specializing in investments within the rapidly evolving landscape of life…

Investing in women’s health innovations.

At Tenmile, we seek to address unmet needs in human health and support the development of a globally significant health science and technology sector in Austral…

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund.

Equity investments in early stage biopharma companies with a clear vision and solid scientific evidence.